Marker Therapeutics (MRKR) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Technology overview

• MAR-T platform offers a natural, non-genetically modified T-cell therapy targeting multiple tumor antigens, with a first-in-class profile and unique mechanism compared to CAR T and other cell therapies.

• Manufacturing process is straightforward, with a current vein-to-vein time of 22 days, aiming to reduce to 17 days this year.

• The technology is licensed from Baylor College of Medicine and has received over $30 million in non-dilutive government funding.

Clinical data and efficacy

• Lead asset MT-601 has shown a 66% overall response rate in non-Hodgkin lymphoma and 78% in Hodgkin lymphoma, including patients refractory to multiple prior treatments.

• Durable responses observed, with some patients maintaining response beyond one year and aiming to replicate Baylor data showing up to five years of sustained response.

• Efficacy seen even at lower dose levels, with ongoing dose escalation up to 400 million cells.

Safety and differentiation

• Excellent safety profile with no ICANS, HLH, or dose-limiting toxicities; only grade 1 CRS (fever) reported.

• The product’s natural, non-genetically engineered nature contributes to its favorable safety and differentiates it from CAR T therapies.